Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
|Articles|July 29, 2022
News Roundup: July 25 to July 29
Author(s)Miranda Hester
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
WHO Declares Monkeypox a Global Health Emergency
The decision comes following reports of 16,000 cases across 75 countries and territories around the world.
Switching Drugs Effective in Treating Diabetic Macular Edema
Research examines whether a step-approach with treatment for macular edema produces positive results.
Drug Overdose Death Totals for 2020 Show Race-Based Disparities
Fentanyl, COVID-19 pandemic likely factors in 30% increase from previous year.
Diabetes Medications Find a Second Life as Weight-Loss Drugs
Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite, but the cost-effectiveness is in question with many payers saying no to coverage.
Risk of Diabetes, Cardiovascular Disease Higher After COVID-19
Research indicates that the risk of certain conditions becomes significantly increased following a bout of COVID-19.
Advertisement
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
3
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
4
Pharmacists Step Up on Test-To-Treat This American Pharmacist Month
5